| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to adv...
																	
																	With over 120 issued and pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sens...
																	GLP study marks a key milestone in Autonomix's path to achieve regulatory approvalsCompany remains on track to submit Inves...
																	New longer-term post hoc analysis results of responders (n=6)1 showed long-lasting, durable pain reduction of nearly 66%, or a ...
																	
																	On August 25, 2025, Autonomix Medical, Inc. (the "Company") entered into a purchase agreement, dated as of August 25, 2...
																	Global patent estate encompasses 80 issued patents and 40 pending patent applicationsStrengthens strategic position in a multi-...